Beschreibung
Pluripotent human embryonic stem cells (hESC) offer an inexhaustible source of replacement cells to heal the damaged or lost tissues that have naturally limited capacity for repair. In regenerative medicine, hESC research holds huge promise for treating major human diseases challenging traditional medicine. Emerging PluriXcel technology enables de novo derivation of high quality clinical-grade hESC lines and direct conversion of such nonfunctional pluripotent cells by small molecule induction into a large commercial scale of functional human neuronal or cardiomyocyte derivatives, which not only constitutes clinically representative progresses in both human neuronal and cardiac therapeutic products for treating a wide range of incurable or hitherto untreatable neurological and heart diseases, but also offer manufacturing innovations for production scale-up and creation of replacement tissue and organ products. Medical and manufacturing innovations of PluriXcel technology provide life scientists and clinicians with novel, efficient, and powerful resources and tools to address major health concerns, which will shape the future of medicine and bring new therapeutics into the market.
Autorenporträt
Dr. Xuejun H Parsons received PhD from Cornell University. Following PostDoc training in molecular biology at University of California at San Diego, she was awarded NIH grants for career transition into human stem cell field. She is inventor of patents for PluriXcel technology breakthroughs and co-founder of several regenerative medicine startups.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
